Moderna Inc (MRNA) stock has risen 203.74% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRNA stock a score of 82 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 96. MRNA's rank also includes a long-term technical score of 91. The fundamental score for MRNA is 59. In addition to the average rating from Wall Street analysts, MRNA stock has a mean target price of 162.545. This means analysts expect the stock to decline 19.61% over the next 12 months.
What's Happening with MRNA Stock Today
Moderna Inc (MRNA) stock is lower by -7.61% while the S&P 500 is lower by -0.22% as of 10:42 AM on Monday, Jun 14. MRNA is lower by -$16.65 from the previous closing price of $218.85 on volume of 5,457,782 shares. Over the past year the S&P 500 is higher by 38.20% while MRNA has risen 203.74%. MRNA earned $1.25 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 161.91.